Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.
NEW YORK , Aug. 7, 2026 /PRNewswire/ -- A 22% single-session decline hit Pharming Group (NASDAQ: PHAR) shareholders on July 30, 2026, after the Company reported second quarter revenue of $90.2 million and cut its full-year 2026 revenue outlook. If you held PHAR shares through that drop, you are encouraged to submit your loss information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The numbers investors were given, side by side with the numbers reported: full-year 2026 revenue guidance had been $405 million to $425 million. The revised range is $375 million to $395 million -- roughly $30 million below the prior midpoint. Analyst consensus ahead of the report stood near $419 million.
Q2 revenue of $90.2 million was down 3% year-over-year. RUCONEST sales fell 10% year-over-year to $72.3 million. Diluted EPS came in at $0.002, versus $0.006 in the prior-year period. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors.
Shareholders who lost money on Pharming Group can have their losses reviewed at no cost , or call (212) 363-7500.
Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.
Frequently Asked Questions About the PHAR Investigation
Q: How much did PHAR stock drop? A: Shares fell approximately 22% on July 30, 2026, after the Company reported a 3% year-over-year revenue decline to $90.2 million and reduced its full-year 2026 revenue outlook to $375 million to $395 million from $405 million to $425 million. Investors who purchased shares and suffered losses may be eligible to seek recovery.
Q: What is the PHAR investigation about? A: A securities investigation is pending concerning Pharming Group (NASDAQ: PHAR) regarding potentially materially false or misleading statements. Shares fell approximately 22% after the Company disclosed the Q2 2026 revenue shortfall and the reduced full-year outlook, causing losses for shareholders.
Q: Who is eligible to participate in the PHAR investigation? A: Investors who purchased PHAR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do PHAR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500.
Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my PHAR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought PHAR and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis. No upfront fees, no retainer, and no out-of-pocket costs.
Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:\
Levi & Korsinsky, LLP\
Joseph E. Levi, Esq.\
Ed Korsinsky, Esq.\
33 Whitehall Street, 27th Floor\
New York, NY 10004\
Tel: (212) 363-7500\
Fax: (212) 363-7171
Attorney Advertising. Prior results do not guarantee similar outcomes.
View original content to download multimedia: https://www.prnewswire.com/news-releases/pharming-group-phar-securities-investigation-notice---levi--korsinsky-302845698.html
SOURCE Levi & Korsinsky, LLP
/Alibaba%20by%20Photo%20Agency%20via%20Shutterstock.jpg)
/An%20Intel%20sign%20out%20front%20of%20a%20corporate%20office%20by%20wolterke%20via%20Adobe%20Stock.jpeg)